Drug Development

From human skin to human data: Advancing immunogenicity testing with human modelsIn a public workshop organized by the FDA-CRCG group, Dr. Nicolas Gaudenzio, CSO of Genoskin, introduced an innovative platform for assessing immune responses in response to injected substances using human skin explants. His talk, titled "A new in vitro framework for assessing immunogenicity using comprehensive profiling of injectable humanRead more

Skin ModelsNativeSkin®, an immunocompetent human skin model to study antigen uptake and processing by Langerhans cells Research by E. Pagès1, L. Mondoulet3, E. Bonnefont1, E. Braun1, V. Dhelft2, C. Dupont3, H. Sampson2, P. Descargues1 1Genoskin, 2DBV Technologies, 3Hôpital Necker, Université Paris-Descartes Scientific Context Epicutaneous immunotherapy (EPIT) using Viaskin® patches has been shown to induce tolerance in sensitized mice (Dioszeghy, ClinRead more

Top-level science through the eyes of an expert.The eighth Webinar. The next episode of the Genoskin Webinar series is now scheduled on October 17, 2024 at 8 a.m. (PST), 11 a.m. (EST), 5 p.m. (CET). The webinar is open to English-speaking participants with a solid scientific background. Featured speaker is Dr. Manon Scholaert, Scientist at Genoskin. Watch the replayIn thisRead more

Injection-Site PainWhich factors influence pain upon subcutaneous injection?Biologics such as vaccines, insulin, monoclonal antibodies, etc., that are now widely developed need to be administered parenterally. While the intravenous (IV) route has historically been the most widely used,  the subcutaneous (SC) route is now accepted and presented as safe and effective, whether in the context of chronic disease or in palliativeRead more

Assessment of injection site reactionsA new proprietary research tool to identify drug-related immune adverse reactions in human skinToday, biologics represent one of the fastest growing markets within the pharmaceutical industry.The pipeline of biological drugs is growing at a rapid pace with a global market expected to reach over 460 billion USD in 2024 (1). In order to bypass gastric metabolism,Read more

Navigating Unwanted ImmunogenicityPart 3 - Challenges & insights in biologic drug developmentOver the past two and a half decades, biologics development has been growing exponentially, matching the pace of small molecules development in 20221. Biologics, or biopharmaceutical products, encompass a wide range of therapeutic products such as vaccines, monoclonal antibodies, gene and cell therapy, and recombinant and fusion therapeutic proteins.Read more